Corrigendum to: The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company. [Journal of Cancer Policy. 40 (2024):100473.]
Article in Journal of Cancer Policy (September 2024)